Datopotamab Deruxtecan, often abbreviated as DATO, represents a significant advancement in targeted cancer treatment. This innovative antibody-drug conjugate pairs an monoclonal antigen specifically directed at HER-2 https://www.targetmol.com/compound/datopotamab